Sumitomo Dainippon Pharma Oncology

Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, DSP Cancer Institute and Oncology Clinical Development Unit, will collectively be known as Sumitomo Dainippon Pharma Oncology or SDP Oncology. SDP Oncology is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Our robust and diverse pipeline of preclinical and advanced-stage assets spans multiple areas, including oncogenic pathways, survival mechanisms and novel protein interactions, which aim to address unmet clinical needs in oncology. SDP Oncology encompasses discovery research, external innovation, clinical development and commercialization. The company has teams in Lehi, Utah, Tokyo and Osaka, Japan as well as Cambridge, Massachusetts. At SDP Oncology, we believe in the power of science – and our people – to usher in breakthrough innovation that will positively impact patients with cancer today and for generations to come.